Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 59 entries
Sorted by: Best Match Show Resources per page
When less is more - efficacy with less toxicity at the ED50.

British journal of clinical pharmacology

Dimmitt S, Stampfer H, Martin JH.
PMID: 28387051
Br J Clin Pharmacol. 2017 Jul;83(7):1365-1368. doi: 10.1111/bcp.13281. Epub 2017 Apr 06.

No abstract available.

Cite
Dimmitt S, Stampfer H, Martin JH. When less is more - efficacy with less toxicity at the ED50. Br J Clin Pharmacol. 2017;83(7):1365-1368doi: 10.1111/bcp.13281.
Dimmitt, S., Stampfer, H., & Martin, J. H. (2017). When less is more - efficacy with less toxicity at the ED50. British journal of clinical pharmacology, 83(7), 1365-1368. https://doi.org/10.1111/bcp.13281
Dimmitt, Simon, et al. "When less is more - efficacy with less toxicity at the ED50." British journal of clinical pharmacology vol. 83,7 (2017): 1365-1368. doi: https://doi.org/10.1111/bcp.13281
Dimmitt S, Stampfer H, Martin JH. When less is more - efficacy with less toxicity at the ED50. Br J Clin Pharmacol. 2017 Jul;83(7):1365-1368. doi: 10.1111/bcp.13281. Epub 2017 Apr 06. PMID: 28387051; PMCID: PMC5465328.
Copy Download .nbib Format: NLM
Interindividual Variation in Source-Specific Doses is a Determinant of Health Impacts of Combined Chemical Exposures.

Risk analysis : an official publication of the Society for Risk Analysis

Price P.
PMID: 32671861
Risk Anal. 2020 Dec;40(12):2572-2583. doi: 10.1111/risa.13550. Epub 2020 Jul 15.

All individuals are exposed to multiple chemicals from multiple sources. These combined exposures are a concern because they may cause adverse effects that would not occur from an exposure recieved from any single source. Studies of combined chemical exposures,...

Cite
Price P. Interindividual Variation in Source-Specific Doses is a Determinant of Health Impacts of Combined Chemical Exposures. Risk Anal. 2020;40(12):2572-2583doi: 10.1111/risa.13550.
Price, P. (2020). Interindividual Variation in Source-Specific Doses is a Determinant of Health Impacts of Combined Chemical Exposures. Risk analysis : an official publication of the Society for Risk Analysis, 40(12), 2572-2583. https://doi.org/10.1111/risa.13550
Price, Paul. "Interindividual Variation in Source-Specific Doses is a Determinant of Health Impacts of Combined Chemical Exposures." Risk analysis : an official publication of the Society for Risk Analysis vol. 40,12 (2020): 2572-2583. doi: https://doi.org/10.1111/risa.13550
Price P. Interindividual Variation in Source-Specific Doses is a Determinant of Health Impacts of Combined Chemical Exposures. Risk Anal. 2020 Dec;40(12):2572-2583. doi: 10.1111/risa.13550. Epub 2020 Jul 15. PMID: 32671861; PMCID: PMC7818457.
Copy Download .nbib Format: NLM
A Review of Recent Advances in Benchmark Dose Methodology.

Risk analysis : an official publication of the Society for Risk Analysis

Jensen SM, Kluxen FM, Ritz C.
PMID: 31046141
Risk Anal. 2019 Oct;39(10):2295-2315. doi: 10.1111/risa.13324. Epub 2019 May 02.

In this review, recent methodological developments for the benchmark dose (BMD) methodology are summarized. Specifically, we introduce the advances for the main steps in BMD derivation: selecting the procedure for defining a BMD from a predefined benchmark response (BMR),...

Cite
Jensen SM, Kluxen FM, Ritz C. A Review of Recent Advances in Benchmark Dose Methodology. Risk Anal. 2019;39(10):2295-2315doi: 10.1111/risa.13324.
Jensen, S. M., Kluxen, F. M., & Ritz, C. (2019). A Review of Recent Advances in Benchmark Dose Methodology. Risk analysis : an official publication of the Society for Risk Analysis, 39(10), 2295-2315. https://doi.org/10.1111/risa.13324
Jensen, Signe M, et al. "A Review of Recent Advances in Benchmark Dose Methodology." Risk analysis : an official publication of the Society for Risk Analysis vol. 39,10 (2019): 2295-2315. doi: https://doi.org/10.1111/risa.13324
Jensen SM, Kluxen FM, Ritz C. A Review of Recent Advances in Benchmark Dose Methodology. Risk Anal. 2019 Oct;39(10):2295-2315. doi: 10.1111/risa.13324. Epub 2019 May 02. PMID: 31046141.
Copy Download .nbib Format: NLM
The use of epidemiological data in risk assessment.

Regulatory toxicology and pharmacology : RTP

Swaen GM.
PMID: 3222484
Regul Toxicol Pharmacol. 1988 Dec;8(4):422-30. doi: 10.1016/0273-2300(88)90041-4.

Next to toxicological data, epidemiological studies form the scientific basis for risk assessment. Both approaches have their particular advantages and limitations. The most important limitation of epidemiological studies is the lack of exact data on past exposures. Their most...

Cite
Swaen GM. The use of epidemiological data in risk assessment. Regul Toxicol Pharmacol. 1988;8(4):422-30doi: 10.1016/0273-2300(88)90041-4.
Swaen, G. M. (1988). The use of epidemiological data in risk assessment. Regulatory toxicology and pharmacology : RTP, 8(4), 422-30. https://doi.org/10.1016/0273-2300(88)90041-4
Swaen, G M. "The use of epidemiological data in risk assessment." Regulatory toxicology and pharmacology : RTP vol. 8,4 (1988): 422-30. doi: https://doi.org/10.1016/0273-2300(88)90041-4
Swaen GM. The use of epidemiological data in risk assessment. Regul Toxicol Pharmacol. 1988 Dec;8(4):422-30. doi: 10.1016/0273-2300(88)90041-4. PMID: 3222484.
Copy Download .nbib Format: NLM
Response to "Pharmacometric Approach to Evaluate Drug Dosing Adherence".

Clinical pharmacology and therapeutics

Ding J, Hoglund RM, Tarning J.
PMID: 33219542
Clin Pharmacol Ther. 2021 Jul;110(1):24-25. doi: 10.1002/cpt.2084. Epub 2020 Nov 20.

No abstract available.

Cite
Ding J, Hoglund RM, Tarning J. Response to "Pharmacometric Approach to Evaluate Drug Dosing Adherence". Clin Pharmacol Ther. 2020;110(1):24-25doi: 10.1002/cpt.2084.
Ding, J., Hoglund, R. M., & Tarning, J. (2021). Response to "Pharmacometric Approach to Evaluate Drug Dosing Adherence". Clinical pharmacology and therapeutics, 110(1), 24-25. https://doi.org/10.1002/cpt.2084
Ding, Junjie, et al. "Response to "Pharmacometric Approach to Evaluate Drug Dosing Adherence"." Clinical pharmacology and therapeutics vol. 110,1 (2021): 24-25. doi: https://doi.org/10.1002/cpt.2084
Ding J, Hoglund RM, Tarning J. Response to "Pharmacometric Approach to Evaluate Drug Dosing Adherence". Clin Pharmacol Ther. 2021 Jul;110(1):24-25. doi: 10.1002/cpt.2084. Epub 2020 Nov 20. PMID: 33219542; PMCID: PMC8359226.
Copy Download .nbib Format: NLM
Is event-driven PrEP dosing for HIV as effective as daily dosing?.

The Journal of family practice

Olsen T, Lally-Montgomery Z, Kelsberg G, Safranek S, Neher J.
PMID: 34410919
J Fam Pract. 2021 Jun;70(5):253-255. doi: 10.12788/jfp.0207.

PROBABLY, although there are no head-to-head trials comparing the 2 dosing regimens. Event-driven pre-exposure prophylaxis (PrEP) dosing reduces HIV conversion by 86% compared to placebo (strength of recommendation [SOR]: B, large randomized controlled trial [RCT]). Daily PrEP reduces HIV...

Cite
Olsen T, Lally-Montgomery Z, Kelsberg G, et al. Is event-driven PrEP dosing for HIV as effective as daily dosing?. J Fam Pract. 2021;70(5):253-255doi: 10.12788/jfp.0207.
Olsen, T., Lally-Montgomery, Z., Kelsberg, G., Safranek, S., & Neher, J. (2021). Is event-driven PrEP dosing for HIV as effective as daily dosing?. The Journal of family practice, 70(5), 253-255. https://doi.org/10.12788/jfp.0207
Olsen, Tory, et al. "Is event-driven PrEP dosing for HIV as effective as daily dosing?." The Journal of family practice vol. 70,5 (2021): 253-255. doi: https://doi.org/10.12788/jfp.0207
Olsen T, Lally-Montgomery Z, Kelsberg G, Safranek S, Neher J. Is event-driven PrEP dosing for HIV as effective as daily dosing?. J Fam Pract. 2021 Jun;70(5):253-255. doi: 10.12788/jfp.0207. PMID: 34410919.
Copy Download .nbib Format: NLM
Precision Dosing: An Industry Perspective.

Clinical pharmacology and therapeutics

Peck RW.
PMID: 33107023
Clin Pharmacol Ther. 2021 Jan;109(1):47-50. doi: 10.1002/cpt.2064. Epub 2020 Oct 26.

No abstract available.

Cite
Peck RW. Precision Dosing: An Industry Perspective. Clin Pharmacol Ther. 2020;109(1):47-50doi: 10.1002/cpt.2064.
Peck, R. W. (2021). Precision Dosing: An Industry Perspective. Clinical pharmacology and therapeutics, 109(1), 47-50. https://doi.org/10.1002/cpt.2064
Peck, Richard W. "Precision Dosing: An Industry Perspective." Clinical pharmacology and therapeutics vol. 109,1 (2021): 47-50. doi: https://doi.org/10.1002/cpt.2064
Peck RW. Precision Dosing: An Industry Perspective. Clin Pharmacol Ther. 2021 Jan;109(1):47-50. doi: 10.1002/cpt.2064. Epub 2020 Oct 26. PMID: 33107023; PMCID: PMC7820949.
Copy Download .nbib Format: NLM
A validated UHPLC-MS/MS method for determination of TQ-B3203 in human plasma and its application to a pharmacokinetic study in Chinese patients with advanced solid tumor.

Journal of separation science

Yang F, Zhou J, Bo Y, Yin H, Liu XH, Li J.
PMID: 33340437
J Sep Sci. 2021 Mar;44(5):945-953. doi: 10.1002/jssc.202001023. Epub 2021 Jan 18.

TQ-B3203 is a new topoisomerase I inhibitor derived from camptothecin. In this paper, a simple and reliable ultra high-performance liquid chromatography-tandem mass spectrometric method was developed and validated for determination of TQ-B3203 in human plasma with TQ-B3203-d

Cite
Yang F, Zhou J, Bo Y, et al. A validated UHPLC-MS/MS method for determination of TQ-B3203 in human plasma and its application to a pharmacokinetic study in Chinese patients with advanced solid tumor. J Sep Sci. 2021;44(5):945-953doi: 10.1002/jssc.202001023.
Yang, F., Zhou, J., Bo, Y., Yin, H., Liu, X. H., & Li, J. (2021). A validated UHPLC-MS/MS method for determination of TQ-B3203 in human plasma and its application to a pharmacokinetic study in Chinese patients with advanced solid tumor. Journal of separation science, 44(5), 945-953. https://doi.org/10.1002/jssc.202001023
Yang, Fen, et al. "A validated UHPLC-MS/MS method for determination of TQ-B3203 in human plasma and its application to a pharmacokinetic study in Chinese patients with advanced solid tumor." Journal of separation science vol. 44,5 (2021): 945-953. doi: https://doi.org/10.1002/jssc.202001023
Yang F, Zhou J, Bo Y, Yin H, Liu XH, Li J. A validated UHPLC-MS/MS method for determination of TQ-B3203 in human plasma and its application to a pharmacokinetic study in Chinese patients with advanced solid tumor. J Sep Sci. 2021 Mar;44(5):945-953. doi: 10.1002/jssc.202001023. Epub 2021 Jan 18. PMID: 33340437.
Copy Download .nbib Format: NLM
Perspectives on Model-Informed Precision Dosing in the Digital Health Era: Challenges, Opportunities, and Recommendations.

Clinical pharmacology and therapeutics

Kluwe F, Michelet R, Mueller-Schoell A, Maier C, Klopp-Schulze L, van Dyk M, Mikus G, Huisinga W, Kloft C.
PMID: 33068303
Clin Pharmacol Ther. 2021 Jan;109(1):29-36. doi: 10.1002/cpt.2049. Epub 2020 Oct 17.

No abstract available.

Cite
Kluwe F, Michelet R, Mueller-Schoell A, et al. Perspectives on Model-Informed Precision Dosing in the Digital Health Era: Challenges, Opportunities, and Recommendations. Clin Pharmacol Ther. 2020;109(1):29-36doi: 10.1002/cpt.2049.
Kluwe, F., Michelet, R., Mueller-Schoell, A., Maier, C., Klopp-Schulze, L., van Dyk, M., Mikus, G., Huisinga, W., & Kloft, C. (2021). Perspectives on Model-Informed Precision Dosing in the Digital Health Era: Challenges, Opportunities, and Recommendations. Clinical pharmacology and therapeutics, 109(1), 29-36. https://doi.org/10.1002/cpt.2049
Kluwe, Franziska, et al. "Perspectives on Model-Informed Precision Dosing in the Digital Health Era: Challenges, Opportunities, and Recommendations." Clinical pharmacology and therapeutics vol. 109,1 (2021): 29-36. doi: https://doi.org/10.1002/cpt.2049
Kluwe F, Michelet R, Mueller-Schoell A, Maier C, Klopp-Schulze L, van Dyk M, Mikus G, Huisinga W, Kloft C. Perspectives on Model-Informed Precision Dosing in the Digital Health Era: Challenges, Opportunities, and Recommendations. Clin Pharmacol Ther. 2021 Jan;109(1):29-36. doi: 10.1002/cpt.2049. Epub 2020 Oct 17. PMID: 33068303.
Copy Download .nbib Format: NLM
Similarities between the Yin/Yang Doctrine and Hormesis in Toxicology and Pharmacology.

Trends in pharmacological sciences

Sun H, Calabrese EJ, Lin Z, Lian B, Zhang X.
PMID: 32564900
Trends Pharmacol Sci. 2020 Aug;41(8):544-556. doi: 10.1016/j.tips.2020.05.004. Epub 2020 Jun 18.

Hormesis is a generalizable dose-response relationship characterized by low-dose stimulation and high-dose inhibition. Despite debate over this biphasic dose-response curve, hormesis is challenging central beliefs in the evaluation of chemicals or drugs and has influenced biological model selection, concentration...

Cite
Sun H, Calabrese EJ, Lin Z, et al. Similarities between the Yin/Yang Doctrine and Hormesis in Toxicology and Pharmacology. Trends Pharmacol Sci. 2020;41(8):544-556doi: 10.1016/j.tips.2020.05.004.
Sun, H., Calabrese, E. J., Lin, Z., Lian, B., & Zhang, X. (2020). Similarities between the Yin/Yang Doctrine and Hormesis in Toxicology and Pharmacology. Trends in pharmacological sciences, 41(8), 544-556. https://doi.org/10.1016/j.tips.2020.05.004
Sun, Haoyu, et al. "Similarities between the Yin/Yang Doctrine and Hormesis in Toxicology and Pharmacology." Trends in pharmacological sciences vol. 41,8 (2020): 544-556. doi: https://doi.org/10.1016/j.tips.2020.05.004
Sun H, Calabrese EJ, Lin Z, Lian B, Zhang X. Similarities between the Yin/Yang Doctrine and Hormesis in Toxicology and Pharmacology. Trends Pharmacol Sci. 2020 Aug;41(8):544-556. doi: 10.1016/j.tips.2020.05.004. Epub 2020 Jun 18. PMID: 32564900; PMCID: PMC7302776.
Copy Download .nbib Format: NLM
Implementation of maximin efficient designs in dose-finding studies.

Pharmaceutical statistics

Fackle-Fornius E, Miller F, Nyquist H.
PMID: 25405333
Pharm Stat. 2015 Jan-Feb;14(1):63-73. doi: 10.1002/pst.1660. Epub 2014 Nov 18.

This paper considers the maximin approach for designing clinical studies. A maximin efficient design maximizes the smallest efficiency when compared with a standard design, as the parameters vary in a specified subset of the parameter space. To specify this...

Cite
Fackle-Fornius E, Miller F, Nyquist H. Implementation of maximin efficient designs in dose-finding studies. Pharm Stat. 2014;14(1):63-73doi: 10.1002/pst.1660.
Fackle-Fornius, E., Miller, F., & Nyquist, H. (2015). Implementation of maximin efficient designs in dose-finding studies. Pharmaceutical statistics, 14(1), 63-73. https://doi.org/10.1002/pst.1660
Fackle-Fornius, Ellinor, et al. "Implementation of maximin efficient designs in dose-finding studies." Pharmaceutical statistics vol. 14,1 (2015): 63-73. doi: https://doi.org/10.1002/pst.1660
Fackle-Fornius E, Miller F, Nyquist H. Implementation of maximin efficient designs in dose-finding studies. Pharm Stat. 2015 Jan-Feb;14(1):63-73. doi: 10.1002/pst.1660. Epub 2014 Nov 18. PMID: 25405333.
Copy Download .nbib Format: NLM
Process and assumptions in risk assessment.

Annals of clinical and laboratory science

Hart RW, Turturro A.
PMID: 3777853
Ann Clin Lab Sci. 1986 Sep-Oct;16(5):353-7.

No abstract available.

Cite
Hart RW, Turturro A. Process and assumptions in risk assessment. Ann Clin Lab Sci. 1986;16(5):353-7
Hart, R. W., & Turturro, A. (1986). Process and assumptions in risk assessment. Annals of clinical and laboratory science, 16(5), 353-7.
Hart, R W, and Turturro, A. "Process and assumptions in risk assessment." Annals of clinical and laboratory science vol. 16,5 (1986): 353-7.
Hart RW, Turturro A. Process and assumptions in risk assessment. Ann Clin Lab Sci. 1986 Sep-Oct;16(5):353-7. PMID: 3777853.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 59 entries